{"nctId":"NCT00388973","briefTitle":"Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder","startDateStruct":{"date":"2006-09"},"conditions":["Major Depressive Disorder"],"count":338,"armGroups":[],"interventions":[{"name":"Quetiapine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients, 66 years or older, with a documented clinical diagnosis of MDD.\n\nExclusion Criteria:\n\n* The presence of dementia or mental disorder other than MDD within 6 months of enrolment,\n* Uncontrolled hypertension, substance or alcohol abuse\n* A current diagnosis of cancer or a current or past diagnosis of stroke","healthyVolunteers":false,"sex":"ALL","minimumAge":"66 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9.","description":"MADRS total score (0-60 units), where lower scores indicate less depressive symptoms, calculated as Week 9 value - baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16","spread":"8"},{"groupId":"OG001","value":"-9","spread":"8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-related Quality of Life, Enjoyment and Satisfaction (Q-LES-Q)","description":"Q-LES-Q as percent of maximum (0 to 100%) calculated as Week 9 - baseline, where higher values indicate better quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":"14"},{"groupId":"OG001","value":"9","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline for Satisfaction With Medication From Quality of Life, Enjoyment, Satisfaction Questionaire (Q-LES-Q)","description":"Item 15 the Quality of Life, Enjoyment Satisfaction Questionnaire (score 1 least -5 best) on Q-LES-Q, calculated as Week 9 value - baseline value","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Anxiety Symptoms Measured by Hamilton Anxiety 14 Item Scale (HAM-A)","description":"Change in HAM-A total score (total score 0-56), calculated as Week 9 value - baseline value, where lower scores indicate less anxiety.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11","spread":"6"},{"groupId":"OG001","value":"-5","spread":"8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index","description":"The Pittsburgh Sleep Quality Index is an eighteen questionnaire scored with 7 sleep component scores each on a 0 to 3 scale, total score range from 0 to 21, worst value 21, best value 0","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"4"},{"groupId":"OG001","value":"-3","spread":"4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Suicidal Thoughts as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Item 10","description":"The suicide item is a single item of the Montgomery-Asberg Depression Rating Scale with a range of values from 0 to 6, worst value 6, best value 0","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Somatic Symptoms Cluster From the Hamilton Anxiety Scale (HAM-A)","description":"The Somatic symptom Cluster of the Hamilton Anxiety Scale is a 7 item cluster associated with somatic symptoms \\*somatic muscular, somatic sensory, cardiovascular system, respiratory system, gastrointestinal system, genitourinary system, autonomic system) with a range of values from 0 to 28, worst value 28, best value 0","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":"-15.7"},{"groupId":"OG001","value":"-2","spread":"-14.6"}]}]}]},{"type":"SECONDARY","title":"Tolerability as Measured by Adverse Event Withdrawals During Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":166},"commonTop":["Headache","Dizziness","Somnolence","Dry Mouth"]}}}